Sponsors (30)
The resolution increases public awareness and highlights research gaps for glioblastoma, potentially spurring attention and collaboration, but it is symbolic and does not provide funding or guaranteed policy action for patients.
Patients with glioblastoma, hospitals, and advocacy/nonprofit groups will have research gaps (limited FDA approvals, need for biomarker testing, GTN existence) highlighted, which could help mobilize research funding, collaboration, and policy attention.
Patients with glioblastoma and their caregivers will see increased public awareness and education because July 15, 2026 is designated as Glioblastoma Awareness Day, which may improve early attention to the disease and public understanding.
Patients with glioblastoma will not receive new federal funding or reduced out‑of‑pocket costs from the designation itself, because the observance is symbolic and does not change treatment access or payor coverage.
Patients and caregivers may expect concrete policy action, new treatments, or immediate federal commitments as a result of the designation, but the resolution does not guarantee follow‑on federal measures.
Based on analysis of 1 section of legislative text.
Designates July 15, 2026 as Glioblastoma Awareness Day and records findings about the disease's burden and research needs.
Official title: Expressing support for the designation of July 15, 2026, as "Glioblastoma Awareness Day".
Introduced May 7, 2026 by Roger Williams · Last progress May 7, 2026
Designates July 15, 2026 as Glioblastoma Awareness Day and records congressional findings about the impact of glioblastoma in the United States. The text highlights incidence and mortality estimates, poor survival statistics, diagnostic and treatment challenges, limited FDA-approved therapies, high out-of-pocket costs, the role of patients and caregivers in research, and the National Cancer Institute’s Glioblastoma Therapeutics Network.